Search Results - "Merenich, John A"

Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization by Charles, Evguenia C, Olson, Kari L, Sandhoff, Brian G, McClure, David L, Merenich, John A

“…To describe the rate, potential causes, symptoms, time to onset, and time to resolution of severe transaminitis associated with increased…”
Get more information

Attainment of low-density lipoprotein cholesterol goals in coronary artery disease by Kauffman, Amy B., PharmD, Olson, Kari L., BSc(Pharm), PharmD, Youngblood, Morgan L., PharmD, Zadvorny, Emily B., PharmD, Delate, Thomas, PhD, MS, Merenich, John A., MD

“…Background The National Cholesterol Education Program Guidelines offer an optional low-density lipoprotein cholesterol (LDL-C) goal of less than 70 mg/dL for…”
Get full text

Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization by Sandhoff, Brian G, Nies, Leslie K, Olson, Kari L, Nash, James D, Rasmussen, Jon R, Merenich, John A

“…A clinical pharmacy service for managing the treatment of coronary artery disease in a health maintenance organization is described. Despite the proven…”
Get full text

Positive predictive values of ICD-9 codes to identify patients with stroke or TIA by Olson, Kari L, Wood, Michele D, Delate, Thomas, Lash, Lisa J, Rasmussen, Jon, Denham, Anne M, Merenich, John A

“…To determine the positive predictive values of inpatient and outpatient ICD-9 codes and status code V12.54 for identifying confirmed history of stroke or…”
Get full text

Self-Rated Health Among Patients with Coronary Artery Disease Enrolled in a Cardiovascular Risk Reduction Service by Olson, Kari L, Stiefel, Matt, Ross, Colleen, Stadler, Sheila, Hornak, Roseanne, Sandhoff, Brian, Merenich, John A

“…Little is known about the use of the single self-rated health (SRH) status item measuring health-related quality of life among people with coronary artery…”
Get more information

Atherosclerotic risk factor control in patients with peripheral arterial disease by Rehring, Thomas F., Sandhoff, Brian G., Stolcpart, Ryan S., Merenich, John A., Hollis, H. Whitton

“…The presence of peripheral arterial disease (PAD), even in the absence of overt coronary artery disease (CAD), confers the same relative risk of death from a…”
Get full text

Mortality Reduction Benefits of a Comprehensive Cardiac Care Program for Patients with Occlusive Coronary Artery Disease by Merenich, John A., Olson, Kari L., Delate, Thomas, Rasmussen, Jon, Helling, Dennis K., Ward, David G.

“…Study Objective. To determine the effect of early and sustained enrollment in a comprehensive cardiac care (CCC) program on all‐cause mortality in patients…”
Get full text

Factors Associated with Recurrent Coronary Events Among Patients with Cardiovascular Disease by McConnell, Karen J., Olson, Kari L., Delate, Thomas, Merenich, John A.

“…Study Objective. To determine which factors are associated with recurrent coronary events. Design. Matched, case‐control study. Data Source. Electronic…”
Get full text

Outcomes of patients discharged from pharmacy-managed cardiovascular disease management by Olson, Kari L, Delate, Thomas, Rasmussen, Jon, Humphries, Tammy L, Merenich, John A

“…To evaluate whether patients with coronary artery disease (CAD) discharged from the Clinical Pharmacy Cardiac Risk Service (CPCRS) would maintain their lipid…”
Get full text

The Risk for Significant Creatine Kinase Elevation with Statins by Stolcpart, Ryan S., Olson, Kari L., Delate, Thomas, Rasmussen, Jon, Rehring, Thomas F., Merenich, John A.

“…Background The HMG-CoA reductase inhibitors (statins) are effective for reducing long-term cardiovascular morbidity and mortality in both primary and secondary…”
Get full text

Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease by Rehring, Thomas F., Stolcpart, Ryan S., Sandhoff, Brian G., Merenich, John A., Hollis, H. Whitton

“…Our group and others have previously established that patients with peripheral artery disease (PAD) are significantly undertreated with respect to overall…”
Get full text

Coronary Artery Disease and Hypertension: Outcomes of a Pharmacist-Managed Blood Pressure Program by McConnell, Karen J., Zadvorny, Emily B., Hardy, Angela M., Delate, Thomas, Rasmussen, Jon R., Merenich, John A.

“…Study Objective. To assess the effectiveness of a pharmacist‐managed service in improving hypertension control among patients with coronary artery disease…”
Get full text

Ambulatory treatment gaps in patients with ischemic stroke or transient ischemic attack by Olson, Kari L, Lash, Lisa J, Delate, Thomas, Wood, Michele, Rasmussen, Jon, Denham, Anne M, Merenich, John A

“…This study evaluated goal attainment for patients with a history of non-cardioembolic ischemic stroke (NCIS) or transient ischemic attack (TIA). A…”
Get full text

Low Myopathy Rates Associated with Statins as Monotherapy or Combination Therapy with Interacting Drugs in a Group Model Health Maintenance Organization by Shanahan, Roberta L., Kerzee, Jane A., Sandhoff, Brian G., Carroll, Nikki M., Merenich, John A.

“…Study Objective. Because the risk for myopathy increases when 3‐hydroxy‐3‐methylglutaryl coenzyme A inhibitors (statins) are used with other agents known to…”
Get full text

Angiotensin-converting enzyme inhibitor therapy for coronary artery disease and diabetes mellitus by McConnell, Karen J, Zadvorny, Emily B, Denham, Anne M, Kasten, Shelia L, Hutka, Kara A, Koetting, Cedar R, Merenich, John A

“…To use a population management strategy to increase the proportion of patients with coronary artery disease (CAD) and diabetes receiving target-dose…”
Get full text

The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization by Porter, Julie A, Raebel, Marsha A, Conner, Douglas A, Lanty, Frances A, Vogel, Erin A, Gay, Elizabeth C, Merenich, John A

“…To assess the benefit of sibutramine hydrochloride monohydrate within a weight management program. Prospective randomized controlled trial in a health…”
Get full text

Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente Experience) by Merenich, John A, Lousberg, Tammy R, Brennan, Stacy H, Calonge, Ned B

“…Rocky Mountain Kaiser Permanente has taken aggressive steps to ensure optimal treatment of all modifiable cardiac risk factors, especially low-density…”
Get full text

Clinical Pharmacy Specialist Implementation of Lisinopril Therapy in Patients with Coronary Artery Disease and Diabetes Mellitus by McConnell, Karen J., Humphries, Tammy L., Raebel, Marsha A., Merenich, John A.

“…Study Objective. As the results of the Heart Outcomes Prevention Evaluation trial suggested that patients with both coronary artery disease (CAD) and diabetes…”
Get full text

Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization by Olson, Kari L, Rasmussen, Jon, Sandhoff, Brian G, Merenich, John A

“…Published data indicate that there is a significant treatment gap between the evidence for and the implementation of lipid-lowering therapy and that recidivism…”
Get more information

Triglyceride-Lowering Effects of a Modest Dose of Docosahexaenoic Acid Alone Versus in Combination with Low Dose Eicosapentaenoic Acid in Patients with Coronary Artery Disease and Elevated Triglycerides by Schwellenbach, Lisa J, Olson, Kari L, McConnell, Karen J, Stolcpart, Ryan S, Nash, James D, Merenich, John A

“…BACKGROUND: Hypertriglyceridemia is a risk factor for coronary artery disease (CAD). The American Heart Association recommends 1000 mg of omega-3 fatty acids,…”
Get full text